| Index | Recent Threads | Unanswered Threads | Who's Active | Guidelines | Search |
 |
World Community Grid Forums
Category: Completed Research
Forum: Help Conquer Cancer
Thread: Interesting News Articles About Cancer |
| No member browsing this thread |
|
Thread Status: Active Total posts in this thread: 954
|
|
| Author |
|
|
Former Member
Cruncher Joined: May 22, 2018 Post Count: 0 Status: Offline |
yes in fact many thanks
----------------------------------------cheers jp [Edit 1 times, last edit by Former Member at May 2, 2012 11:40:05 AM] |
||
|
|
jochrupp
Advanced Cruncher Germany Joined: Nov 17, 2004 Post Count: 58 Status: Offline Project Badges: 
|
Hi Jean Pierre,
----------------------------------------seems it belongs to the FAAH section. Best regards, jochrupp  |
||
|
|
Michael2901
Veteran Cruncher Joined: Feb 6, 2009 Post Count: 586 Status: Offline Project Badges: 
|
http://www.medicalnewstoday.com/articles/238018.php
"Article Date: 21 Nov 2011 Brain Cancer Vaccine Shows Positive Results Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced today that its immunotherapeutic vaccine called Rindopepimut showed positive results in prolonging survival in patients with newly diagnosed EGFRvIII-positive glioblastoma (GB), one of the most aggressive forms of brain cancer. 65 patients in 31 locations were choosen for the study known as ACT III The overall historic survival rate for patients with GB selected to match those on the trial was 15.2 months. Rindopepimut targets the tumor-specific molecule, epidermal growth factor receptor variant III (EGFRvIII). EGFRvIII is a mutated form of the epidermal growth factor receptor (EGFR) that is only expressed in cancer cells and not in normal tissue, and is a transforming oncogene that can directly contribute to cancer cell growth. Expression of EGFRvIII is linked to poor long term survival, regardless of other factors, such as extent of resection and age. EGFRvIII has been expressed in 31% of GB tumors when assessed using the Celldex PCR assay. 31 locations participated in the study and results are very consistent with two previous smaller studies with Rindopepimut in GB conducted at M.D. Anderson and Duke University, which showed 24.6 and 24.4 month median OS, respectively, nearly doubling the life expectancy..." |
||
|
|
Michael2901
Veteran Cruncher Joined: Feb 6, 2009 Post Count: 586 Status: Offline Project Badges:
|
http://www.medicalnewstoday.com/articles/238083.php
"Article Date: 22 Nov 2011 Study Identifies Factors Associated With Increased Risk Of Death Among Two-Year Survivors Of Head And Neck Cancer Among patients with head and neck cancer, poor overall quality of life, pain, and continued tobacco use appear to be associated with poorer outcomes and higher mortality rate two years after diagnosis, according to a report in the November issue of the Archives of Otolaryngology - Head & Neck Surgery, one of the JAMA/Archives journals. "A conditional survival rate is the probability of surviving after having already lived for a certain length of time," the authors write as background information in the study. "This concept is important in the care of patients with head and neck cancer because it underlies the intuition of head and neck oncologists that mortality and recurrence rates are lower for patients further out from diagnoses..." |
||
|
|
Michael2901
Veteran Cruncher Joined: Feb 6, 2009 Post Count: 586 Status: Offline Project Badges:
|
http://www.medicalnewstoday.com/releases/238054.php
"Article Date: 23 Nov 2011 Tumor-Homing Peptide Delivers Treatment That Shrinks Tumors And Minimizes Side Effects The trouble with most anti-cancer therapies is that they are lethal to most cells in the body, not just cancer cells. As a result, patients experience side effects like nausea, increased susceptibility to infection, and increased risk of developing secondary cancers later in life. Researchers at Sanford-Burnham Medical Research Institute (Sanford-Burnham) are developing techniques to deliver cancer drugs directly to tumors, increasing their effectiveness and decreasing collateral damage. In a study published the week of November 21 in the Proceedings of the National Academy of Sciences of the USA, a team led by Michiko Fukuda, Ph.D. coupled a cancer drug to a small protein called IF7, which is specifically attracted to the blood vessels that feed tumors. When administered in a mouse model of human colon cancer, IF7 carried the drug directly to tumors, where it suppressed growth at low dosages and with no apparent side effects. These findings suggest that IF7 is an efficient drug delivery vehicle that could be further exploited to target a variety of anti-cancer therapeutics where they're needed most, without harming other tissues. "We can cure terminal stage mice with very large tumors without any side effects simply by giving them this drug coupled with IF7," said Dr. Fukuda, professor in Sanford-Burnham's National Cancer Institute (NCI)-designated Cancer Center and corresponding author of the study..." |
||
|
|
Michael2901
Veteran Cruncher Joined: Feb 6, 2009 Post Count: 586 Status: Offline Project Badges:
|
http://www.medicalnewstoday.com/releases/238155.php
"Article Date: 26 Nov 2011 T-Cell Ability To Target Cancer Restored By Arginine In many cases, tumors suppress a patient's immune system in a way that keeps the cancer safe from immune system attack. This is particularly true for patients with glioblastoma, a primary brain tumor that carries a prognosis of only 12-15 months survival after diagnosis. A study at the University of Colorado Cancer Center, recently published as a featured article in the journal Clinical Cancer Research, shows that treatment with the over-the-counter amino acid arginine may reactivate cancer-fighting T-cells in patients with glioblastoma, thus potentially allowing the immune system to help cleanse the body of cancer. T-cells are the primary agent responsible for anti-tumor immune responses..." |
||
|
|
Michael2901
Veteran Cruncher Joined: Feb 6, 2009 Post Count: 586 Status: Offline Project Badges:
|
http://www.medicalnewstoday.com/releases/239493.php
"Article Date: 21 Dec 2011 Wayne State Study Finds Soybean Compounds Enhances Effects Of Cancer Radiotherapy A Wayne State University researcher has shown that compounds found in soybeans can make radiation treatment of lung cancer tumors more effective while helping to preserve normal tissue. A team led by Gilda Hillman, Ph.D., professor of radiation oncology at Wayne State University's School of Medicine and the Barbara Ann Karmanos Cancer Institute, had shown previously that soy isoflavones, a natural, nontoxic component of soybeans, increase the ability of radiation to kill cancer cells in prostate tumors by blocking DNA repair mechanisms and molecular survival pathways, which are turned on by the cancer cells to survive the damage radiation causes. At the same time, isoflavones act to reduce damage caused by radiation to surrounding cells of normal, noncancerous tissue. This was shown in a clinical trial conducted at WSU and Karmanos for prostate cancer patients treated with radiotherapy and soy tablets..." |
||
|
|
Michael2901
Veteran Cruncher Joined: Feb 6, 2009 Post Count: 586 Status: Offline Project Badges:
|
http://www.medicalnewstoday.com/releases/239494.php
"Article Date: 21 Dec 2011 Targeting EETs To Treat Cardiovascular Disease May Prove A Double-Edged Sword A group of small molecules called EETs - currently under scrutiny as possible treatment targets for a host of cardiovascular diseases - may also drive the growth and spread of cancer, according to researchers at the Dana-Farber/Children's Hospital Cancer Center (DF/CHCC) and other institutions. Their findings also raise the possibility that drugs that block EETs could serve as a new avenue for cancer treatment. This study, led by Dipak Panigrahy, MD, of DF/CHCC and the Vascular Biology Program at Children's Hospital Boston, appeared online December 19 in the Journal of Clinical Investigation. EETs (or epoxyeicosatrienoic acids) are small fatty molecules, part of a larger family of lipids normally produced by the endothelial cells that line blood vessels to control inflammation and the response to injury. These molecules are also potent regulators of blood pressure, leading pharmaceutical companies to investigate compounds that raise EET levels for the treatment of nearly 20 cardiovascular diseases, including hypertension, stroke, and diabetes. However, little work has been done to learn whether these molecules themselves might have some role to play in tumor growth or progression. This is despite evidence that enzymes that process EETs are associated with cancer, and that EETs can promote angiogenesis - the growth of blood vessels..." |
||
|
|
Michael2901
Veteran Cruncher Joined: Feb 6, 2009 Post Count: 586 Status: Offline Project Badges:
|
http://www.medicalnewstoday.com/releases/239702.php
"Article Date: 24 Dec 2011 Drugs Used To Overcome Cancer May Also Combat Antibiotic Resistance Drugs used to overcome cancer may also combat antibiotic resistance, finds a new study led by Gerry Wright, scientific director of the Michael G. DeGroote Institute for Infectious Disease Research at McMaster University. "Our study found that certain proteins, called kinases, that confer antibiotic resistance are structurally related to proteins important in cancer," says Wright about the study published in Chemistry & Biology. "The pharmaceutical sector has made a big investment in targeting these proteins, so there are a lot of compounds and drugs out there that, although they were designed to overcome cancer, they can in fact be looked at with fresh eyes and maybe repurposed to address the problem of antibiotic resistance..." |
||
|
|
Michael2901
Veteran Cruncher Joined: Feb 6, 2009 Post Count: 586 Status: Offline Project Badges:
|
http://www.medicalnewstoday.com/releases/239182.php
"Article Date: 25 Dec 2011 Lifestyle And Environmental Factors Associated With Cancer Risk It has been well established that certain lifestyle habits relate to the risk of certain cancers (e.g., smoking and lung cancer). In a well-done analysis, the authors estimate the proportion of cancer in the population associated with a variety of lifestyle and environmental factors. They find that smoking has, by far, the largest effect on the risk of cancer, with 19.4% of cancer cases in the UK attributable to tobacco use. A poor diet (less intake of fruits and vegetables and fibre and greater intake of meat and salt), obesity, and alcohol are the next most important factors that relate to cancer, with alcohol being calculated to relate to 4.0% of cancer cases in the UK..." |
||
|
|
|